APOXIS S.A. Receives FDA Orphan Medicinal Product Designation For APO200 For The Treatment Of XLHED

Apoxis SA, a Swiss biopharmaceutical company developing oncology and immunology products, today announced it has received Orphan Medicinal Product designation from the FDA for its rare disease protein therapeutic, APO200.